DURHAM, N.C. & SEATTLE--January 12, 2025--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and...
The company pursued development of a reversible inhibitor of monoamine oxidase (MAOI) for treatment resistant depression. In addition, the company assembled a pipeline of selective cannabinoid compounds for the treatment of pain, glaucoma, and obesity.
CeNeRx BioPharma
Cary, NC
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.